Glenmark Pharmaceuticals LtdNSE: GLENMARK
Open the Glenmark Pharmaceuticals Ltd page
Follow Glenmark Pharmaceuticals LtdFree account. Get a note when Glenmark Pharmaceuticals Ltd files.
Q1 FY27 results analysis · July 31, 2026

Glenmark Pharmaceuticals Q1 FY27 Results Analysis: Revenue Surges 23%, Zero Gross Debt Achieved

+930.3%PAT year on year, Rs. 482.83 Cr
Cofacto ResearchPublished July 31, 20262 min readPositive read
Quick summary

Glenmark Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 4,018.48 Cr (+23.10% YoY) and PAT growth of +930.34% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 31, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 4,018.48 Cr (+23.10% YoY)
PAT (Q1)Rs. 482.83 Cr (+930.34% YoY)
EBITDA margin20.03% (+225 bps YoY)
EPS (Q1)Rs. 17.11 (+930.72% YoY)
Market capRs. 63,019.26 Cr
CMPRs. 2,233.90

Quarter Snapshot

Revenue grew 23.1% YoY to a record Q1, EBITDA margin improved 225 bps to 20.03%, but missed the 23% target. Zero gross debt was achieved and Monroe facility restart provides a catalyst, though subsidiary losses remain a drag.

Key Investment Insights

Key Positives

  • Revenue of Rs.4,018.48 Cr, highest-ever Q1, grew 23.1% YoY.
  • EBITDA margin improved 225 bps YoY to 20.03%.
  • PAT of Rs.482.83 Cr (EPS Rs.17.11) on a clean quarter with zero exceptional items.
  • Zero gross debt achieved as of FY26, meeting Glenmark 3.0 target.
  • Monroe facility cleared VAI status, restarting commercial manufacturing.
  • Gross margin stable at ~69% despite API cost inflation.

Risk Factors

  • EBITDA margin of 20.03% missed the company's 23% target by ~3pp.
  • Subsidiaries were a net drag of Rs.252.81 Cr on consolidated PAT.
  • Finance costs rose 26.7% QoQ to Rs.54 Cr, partly due to Nebulizer transaction.
  • Cash tax rate of 32.77% is above effective rate of 24.96%, indicating timing differences.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.